Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcia is an over-the-counter calcium and vitamin D3 supplement marketed in Canada by Medexus Pharmaceuticals. It is formulated as a chewable tablet containing calcium carbonate and cholecalciferol (vitamin D3). Calcium carbonate provides elemental calcium, which is essential for bone mineralization, muscle contraction, and nerve transmission, and acts as an agonist at the calcium-sensing receptor (CaSR). Cholecalciferol is a vitamin D3 analog that is metabolized to its active form, calcitriol, which acts as an agonist at the vitamin D receptor (VDR) to enhance intestinal absorption of calcium. Calcia is approved and used for the prevention and treatment of calcium and vitamin D deficiencies, as well as supportive therapy for osteoporosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + cholecalciferol (Medexus Pharmaceuticals).